CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) — Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical firm with the aim to higher the lives of individuals impacted by kidney illness, in the present day introduced the pricing of its underwritten public providing (the “Offering”) of 25,000,000 shares of its frequent inventory at a public providing value of $2.00 per share. All shares are being provided by Akebia. The gross proceeds to Akebia from the Offering, earlier than deducting underwriting reductions, commissions and different providing bills, are anticipated to be $50.0 million. As well as, Akebia has granted the underwriters a 30-day choice to buy as much as 3,750,000 extra shares of its frequent inventory on the public providing value, much less underwriting reductions and commissions. The Offering is anticipated to shut on March 21, 2025, topic to the satisfaction of customary closing situations.
Leerink Companions and Piper Sandler & Co. are appearing as joint bookrunning managers for the Offering. BTIG, LLC is appearing as lead supervisor and H.C. Wainwright & Co. is appearing as co-manager for the Offering.
The shares are being provided by Akebia pursuant to a shelf registration assertion that was filed with the Securities and Trade Fee (“SEC”) on September 3, 2024 and declared efficient by the SEC on September 12, 2024.
The Offering is being made solely by means of a prospectus and prospectus complement that kind an element of the registration assertion. A preliminary prospectus complement referring to and describing the phrases of the Offering has been filed with the SEC and could also be obtained without spending a dime by visiting the SEC’s web site at www.sec.gov. A closing prospectus complement referring to the Offering can be filed with the SEC. When accessible, copies of the ultimate prospectus complement and the accompanying prospectus may additionally be obtained by contacting: Leerink Companions LLC, Consideration: Syndicate Division, 53 State Road, fortieth Ground, Boston, MA 02109, by phone at (800)-808-7525, ext. 6105, or by e mail at syndicate@leerink.com; or Piper Sandler & Co., Consideration: Prospectus Division, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by phone at (800)-747-3924, or by e mail at prospectus@psc.com.
This press launch shall not represent a proposal to promote, or a solicitation of a proposal to purchase these securities, nor shall there be any sale of, these securities in any state or jurisdiction wherein such provide, solicitation or sale could be illegal previous to registration or qualification below the securities legal guidelines of any such state or jurisdiction.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a completely built-in biopharmaceutical firm with the aim to higher the lives of individuals impacted by kidney illness. Akebia was based in 2007 and is headquartered in Cambridge, Massachusetts.
Ahead-Wanting Statements
This press launch incorporates forward-looking statements inside the which means of the Non-public Securities Litigation Reform Act of 1995, as amended, that contain substantial dangers and uncertainties. The phrases “anticipate,” “consider,” “construct,” “can,” “ponder,” “proceed,” “might,” “ought to,” “designed,” “estimate,” “undertaking,” “anticipate,” “forecast,” “future,” “aim,” “intend,” “doubtless,” “might,” “plan,” “doable,” “potential,” “predict,” “technique,” “search,” “goal,” “will,” “would,” derivatives of these phrases, and related references are supposed to establish forward-looking statements, though not all forward-looking statements comprise these figuring out phrases. These forward-looking statements embody, amongst others, statements relating to the Offering, together with the satisfaction of customary closing situations referring to the Offering and the anticipated closing of the Offering. Precise outcomes might differ materially from these projected or implied in these forward-looking statements. Components which will trigger such a distinction embody, with out limitation, dangers and uncertainties associated to market situations which will have an effect on the timing, phrases and situations of the Offering and the satisfaction of closing situations associated to the Offering. There will be no assurance that Akebia will have the ability to full the Offering on the anticipated phrases, or in any respect. You shouldn’t place undue reliance on these forward-looking statements. Further dangers and uncertainties referring to the Offering, Akebia and its enterprise embody these recognized below the heading “Threat Components” in Akebia’s Annual Report on Kind 10-Okay for the fiscal 12 months ended December 31, 2024, Akebia’s preliminary prospectus complement filed with the SEC on March 19, 2025 and different filings that Akebia might make with the SEC sooner or later. The forward-looking statements contained on this press launch (besides as in any other case famous) communicate solely as of the date hereof, and, besides as required by regulation, Akebia doesn’t undertake, and particularly disclaims, any obligation to replace any forward-looking statements contained on this press launch.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
Supply: Akebia Therapeutics, Inc.
Source link
#Akebia #Therapeutics #Announces #Pricing #Public #Offering #Common #Stock
